Yogurt — Probiotic Strains

Yogurt is defined by its starter cultures — the US FDA standard of identity (21 CFR 131.200) requires that anything labeled "yogurt" be made by culturing milk with two specific bacterial species: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. Modern commercial yogurts often add probiotic adjunct strains (L. acidophilus, L. casei, L. rhamnosus GG, Bifidobacterium animalis subsp. lactis) for additional clinical effects. This deep dive walks through what each strain does, which ones survive gastric transit, how to read a CFU label, and the surprisingly strict ISAPP definition of "probiotic" that most marketing claims do not actually meet.

Table of Contents

  1. The FDA Standard of Identity (21 CFR 131.200)
  2. The Two Starter Cultures — Symbiosis and Fermentation Roles
  3. Probiotic Adjunct Strains (L. acidophilus, L. casei, LGG, Bifidobacterium)
  4. The ISAPP Definition — Why Most "Probiotic" Claims Are Wrong
  5. Surviving Gastric Transit — What Actually Reaches the Gut
  6. CFU Labeling and the End-of-Shelf-Life Requirement
  7. Strain-Specific Evidence Base (LGG, B. lactis DN-173 010, NCFM)
  8. Heat-Treated Yogurt and the Live-Culture Question
  9. Dosing and Practicalities (CFU per Day, Strain Selection)
  10. Cautions (Immunocompromised, Central Lines, Pancreatitis Trial)
  11. Key Research Papers
  12. Connections

The FDA Standard of Identity (21 CFR 131.200)

The legal definition of "yogurt" in the United States is the FDA standard of identity codified at 21 CFR 131.200. The standard, first promulgated in 1981 and updated in 2021, requires that yogurt be produced by culturing cream, milk, or partially skimmed milk with a characterizing bacterial culture that contains Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus. The 2021 update clarified that the live and active cultures must be present at the time of manufacture but did not require any minimum count at the consumer-purchase date — that minimum-count standard is the voluntary National Yogurt Association "Live and Active Cultures" seal (108 CFU/g at the end of shelf life).

The standard further allows optional ingredients including sweeteners, flavorings, color additives, stabilizers, and other dairy-derived ingredients (whey, nonfat milk solids), but the two starter cultures are mandatory. A product made by acidifying milk with citric or other acid (without bacterial fermentation) cannot be labeled yogurt in the US; it can only be labeled "acidified milk product" or similar. EU regulations (CODEX STAN 243-2003 and the EU's own implementing rules) follow a similar two-culture requirement.

This standard matters clinically because it distinguishes true yogurt — with its live cultures and in-situ bacterial enzymes — from heat-treated yogurt-style products (sold shelf-stable in some markets) that contain no live cultures and provide neither the probiotic nor the lactase-delivery effects documented in the clinical literature.

Back to Table of Contents

The Two Starter Cultures — Symbiosis and Fermentation Roles

The two mandatory starter cultures (S. thermophilus and L. bulgaricus) are typically used together because they exhibit a classic mutualistic symbiosis called protocooperation:

The fermentation typically runs for 4-6 hours at 42-43°C (close to optimal growth temperature for both organisms), then cools rapidly to 4°C to slow further acid production and lock in the desired pH and flavor profile.

Back to Table of Contents

Probiotic Adjunct Strains (L. acidophilus, L. casei, LGG, Bifidobacterium)

The two FDA-required starter cultures (S. thermophilus and L. bulgaricus) do not technically meet the rigorous ISAPP definition of "probiotic" — they are starter cultures whose primary role is fermentation, not gut colonization. They do provide benefit (lactose digestion, acetaldehyde, modest immune effects), but most clinically defined probiotic effects come from added adjunct strains. The major adjuncts in commercial yogurt:

The clinical effect of any probiotic is strain-specific, not species-specific. L. rhamnosus GG is not interchangeable with L. rhamnosus HN001 — they have different documented effects despite sharing a species name. Marketing claims that bundle multiple strains under a generic "probiotic blend" without specifying which strains and at what CFU each are nearly useless for predicting clinical effect.

Back to Table of Contents

The ISAPP Definition — Why Most "Probiotic" Claims Are Wrong

The International Scientific Association for Probiotics and Prebiotics (ISAPP) published a 2014 consensus statement (Hill et al., Nature Reviews Gastroenterology & Hepatology) restating and updating the original WHO/FAO definition of probiotic:

"Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host."

The consensus statement spells out three implications that the marketing community routinely violates:

  1. Live — heat-killed or fragmented organisms do not qualify as probiotics, even if they have biological activity (these are now sometimes called "postbiotics" or "paraprobiotics"). Shelf-stable yogurt-style products with no surviving organisms do not contain probiotics under this definition.
  2. Adequate amounts — the dose actually used in the clinical trial that documented the benefit. For LGG, that is typically 109 to 1010 CFU per dose. For Activia's B. lactis DN-173 010, it is 1.25 × 1010 CFU per cup. A product with the strain present at 106 CFU is not "probiotic" at that dose, even if the same strain at higher dose has trial evidence.
  3. Health benefit on the host — the specific benefit claimed must have trial evidence with that specific strain at that specific dose. Extrapolating to other strains or indications is not scientifically defensible.

The ISAPP definition explicitly excludes the two FDA-required yogurt starter cultures (S. thermophilus and L. bulgaricus) from being called probiotics in their starter-culture role, because their primary purpose is fermentation rather than gut effect. However, ISAPP carved out a specific exception in a 2024 update: the live cultures in yogurt that are documented to improve lactose digestion in lactose-maldigesting individuals (the EFSA-approved health claim) can be called "probiotic" for that specific use.

Back to Table of Contents

Surviving Gastric Transit — What Actually Reaches the Gut

The gastric environment is hostile to most bacteria — fasted gastric pH can drop to 1.5-2.0, well below the lethal threshold for many Lactobacillus species. Survival of orally ingested probiotics depends on several factors:

Even surviving strains do not generally colonize permanently. Most ingested probiotics are transient — they pass through the gut producing effects (lactase activity, immune modulation, metabolite production) during transit, but disappear from stool within a few days of discontinuation. This is why effects require ongoing consumption rather than a one-time "reset" dose, contrary to common marketing.

Back to Table of Contents

CFU Labeling and the End-of-Shelf-Life Requirement

CFU (colony-forming unit) is the unit count for live bacteria — one CFU is one viable organism capable of forming a colony when plated on agar. CFU declines over the shelf life of a yogurt as the organisms metabolize remaining substrate, encounter acid stress, and gradually die off. Two key labeling conventions:

For clinical effect, target the dose used in the trial that documented your specific desired benefit. Examples: 1010 CFU/day of LGG for AAD prevention; 1.25 × 1010 CFU/day of B. lactis DN-173 010 for gut-transit improvement; 109-1010 CFU/day of L. casei Shirota for elderly respiratory infection reduction.

Back to Table of Contents

Strain-Specific Evidence Base (LGG, B. lactis DN-173 010, NCFM)

A handful of strains have particularly well-developed clinical evidence bases:

For the related topic of intestinal microbiome restoration in SIBO and IBS, see those pages — probiotic yogurt is generally well-tolerated and may help symptoms, though it is not a primary treatment for SIBO itself.

Back to Table of Contents

Heat-Treated Yogurt and the Live-Culture Question

Some commercial yogurts are pasteurized after fermentation to extend shelf life (allowing storage at room temperature rather than refrigeration). This is common in some European markets and in shelf-stable yogurt drinks. Post-fermentation heat treatment kills the live cultures.

In the US, products that have been heat-treated post-fermentation cannot legally be labeled "yogurt" under the 21 CFR 131.200 standard of identity. They must be labeled "heat-treated yogurt" or "yogurt-style product" or similar qualifier.

The clinical implication: heat-treated yogurt provides the nutrient density of yogurt (protein, calcium, B12) but neither the probiotic effect nor the in-situ lactase delivery. For lactose-intolerant individuals specifically, heat-treated yogurt is NOT a substitute for live yogurt — it will not improve lactose digestion. Always check the label for "live and active cultures" or the NYA seal if probiotic effect or lactose tolerance is the intended benefit.

Note that some legitimate dairy products fermented similarly — sour cream, crème fraîche — are also heat-treated and contain no live cultures despite being products of bacterial fermentation. They are also not substitutes for live yogurt.

Back to Table of Contents

Dosing and Practicalities (CFU per Day, Strain Selection)

For general gut-health support in healthy adults, daily consumption of any yogurt with live cultures meeting the NYA standard (108 CFU/g) provides reasonable probiotic exposure. A 6-ounce (170 g) serving delivers approximately 1.7 × 1010 CFU total, well above thresholds for documented effects.

For specific clinical applications, choose products documenting the strain shown to work for that condition:

For long-term general consumption, plain unsweetened yogurt with added fresh fruit at home is cleaner than commercial fruit-on-the-bottom varieties that add 18-24 g sugar per cup. Greek-strained yogurt provides higher protein at the cost of lower lactose (see Greek vs Regular) but the probiotic content is comparable assuming both products contain live and active cultures.

Back to Table of Contents

Cautions (Immunocompromised, Central Lines, Pancreatitis Trial)

Back to Table of Contents

Key Research Papers

  1. Hill C et al. (2014). Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. — PMID 24912386
  2. Gorbach SL, Goldin BR (1989). The discovery of Lactobacillus rhamnosus GG. Annales Medicinae Experimentalis et Biologiae Fenniae. — PubMed: LGG discovery
  3. Goldenberg JZ et al. (2017). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews. — PMID 29257353
  4. Schnadower D et al. (2018). Lactobacillus rhamnosus GG versus placebo for acute gastroenteritis in children. NEJM. — PMID 30462938
  5. Besselink MGH et al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial (PROPATRIA). The Lancet. — PMID 18279948
  6. Marteau P et al. (2002). Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women. Alimentary Pharmacology & Therapeutics. — PMID 11982445
  7. EFSA Panel on Dietetic Products, Nutrition and Allergies (2010). Scientific Opinion on the substantiation of health claims related to live yoghurt cultures and improved lactose digestion. EFSA Journal. — PubMed: EFSA opinion
  8. Sanders ME et al. (2019). Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nature Reviews Gastroenterology & Hepatology. — PMID 31296969
  9. Szajewska H, Kolodziej M (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Alimentary Pharmacology & Therapeutics. — PMID 26365389
  10. Mimura T et al. (2004). Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. — PMID 14724148
  11. Sazawal S et al. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infectious Diseases. — PMID 16728323
  12. Suez J et al. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. — PMID 30193113

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents